|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
<i>EGFR</i> exon 19 deletions and L858R mutation in exon 21 are the most common sensitive mutations in lung adenocarcinoma.
|
31064887 |
2019 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 55-year-old female with EGFR mutation (L858R) was diagnosed with lung adenocarcinoma, who was responsive to first-generation EGFR-tyrosine kinase inhibitor (TKI).
|
31382924 |
2019 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
ctDNA of EGFR-TKI sensitizing mutations (mEGFR), L858R substitution and Exon 19 deletion (E19d) mutation, was evaluated using droplet digital PCR (ddPCR) in 81 patients with lung adenocarcinoma which harbored mEGFR in the corresponding tumor tissues.
|
31647198 |
2019 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Clinicopathologic information was analyzed and EGFR mutation results were performed in initial biopsy samples.Seven patients showed transformation from ADC to SCLC, of which 6 patients were 19 del EGFR mutation, only 1 patient is L858R mutations.
|
30896637 |
2019 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Unusual synchronous double primary treatment-naïve lung adenocarcinoma harboring T790M and L858R mutations in early-stage lung cancer.
|
31426797 |
2019 |
|
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Unusual synchronous double primary treatment-naïve lung adenocarcinoma harboring T790M and L858R mutations in early-stage lung cancer.
|
31426797 |
2019 |
|
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 55-year-old female with EGFR mutation (L858R) was diagnosed with lung adenocarcinoma, who was responsive to first-generation EGFR-tyrosine kinase inhibitor (TKI).
|
31382924 |
2019 |
|
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our study suggested the intratumoral heterogeneity of EGFR-activating mutations in lung adenocarcinoma confirmed on the single-cell level, which might be associated with EGFR-TKIs response in lung adenocarcinoma patients harboring the EGFR L858R mutation.
|
31014278 |
2019 |
|
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
<i>EGFR</i> exon 19 deletions and L858R mutation in exon 21 are the most common sensitive mutations in lung adenocarcinoma.
|
31064887 |
2019 |
|
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Clinicopathologic information was analyzed and EGFR mutation results were performed in initial biopsy samples.Seven patients showed transformation from ADC to SCLC, of which 6 patients were 19 del EGFR mutation, only 1 patient is L858R mutations.
|
30896637 |
2019 |
|
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Patients with advanced lung adenocarcinoma with membranous mutant EGFR (19del or 21 L858R) showed significantly longer progression-free survival than those with cytoplasmic mutant EGFR after gefitinib treatment.
|
31228625 |
2019 |
|
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
ctDNA of EGFR-TKI sensitizing mutations (mEGFR), L858R substitution and Exon 19 deletion (E19d) mutation, was evaluated using droplet digital PCR (ddPCR) in 81 patients with lung adenocarcinoma which harbored mEGFR in the corresponding tumor tissues.
|
31647198 |
2019 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
<i>EGFR</i> T790M detection rate in lung adenocarcinomas at baseline using droplet digital PCR and validation by ultra-deep next generation sequencing.
|
31737495 |
2019 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Plasma samples from patients with advanced EGFR-mutated lung adenocarcinoma were analyzed for EGFR T790M, exon 19 deletions, and L858R mutations by both ddPCR and Cobas.
|
30810887 |
2019 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Origin of the T790M mutation and its impact on the clinical outcomes of patients with lung adenocarcinoma receiving EGFR-TKIs.
|
30760406 |
2019 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
<i>EGFR</i> L718Q mutation occurs without T790M mutation in a lung adenocarcinoma patient with acquired resistance to osimertinib.
|
31205925 |
2019 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We describe a 52-year-old man with ISCMs secondary to lung adenocarcinoma who acquired the T790M mutation of the epidermal growth factor receptor (EGFR) after previous use of a first-generation EGFR tyrosine kinase inhibitor (TKI); he was successfully treated with osimertinib.
|
31229973 |
2019 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here, we used afatinib-resistant lung adenocarcinoma cells [AfaR (formerly AFR3) cells], carrying exon 19 deletion/T790M in <i>EGFR</i> To identify the novel resistance mechanisms in post-afatinib treatment, RocR1/RocR2 and OsiR1/OsiR2 cells were established using increasing concentrations of rociletinib and osimertinib, respectively.
|
30322949 |
2019 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Unusual synchronous double primary treatment-naïve lung adenocarcinoma harboring T790M and L858R mutations in early-stage lung cancer.
|
31426797 |
2019 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In the present study, we report cases of two synchronous lung adenocarcinomas composed of two distinct pathological subtypes with different EGFR gene mutations: a homozygous deletion in exon 19 of the papillary adenocarcinoma subtype and a point mutation of L858R in exon 21 of the tubular adenocarcinoma.
|
29090842 |
2018 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
All six L858R-mutant cavitary ADC patients had thick-wall cavity while thick-wall cavity was only identified in one thirds (3/9) of patients with 19DEL.
|
30352571 |
2018 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
All patients were diagnosed with advanced lung adenocarcinoma and harbored EGFR 19del or L858R mutations before treatment.
|
30196239 |
2018 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Patients with the early stage lung adenocarcinoma harboring either 19del or L858R share similar RFS and OS.
|
29026990 |
2018 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Radical resection was performed and confirmed an EGFR exon 21 L858R lung adenocarcinoma.
|
29461911 |
2018 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Compare the complete (CR) and partial response (PR) rates, overall survival (OS), and progression-free survival (PFS) in Hispanic patients with lung adenocarcinoma treated with erlotinib with EGFR mutations (L858R or exon 19 deletion [Del19]) with and without concomitant EGFRamp.
|
30284706 |
2018 |